Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial

Official title:
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients With Colorectal Cancer and Other Solid Tumors

Status Completed

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable colorectal cancer or solid tumor. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of suberoylanilide hydroxamic acid when administered with fluorouracil, leucovorin calcium, and oxaliplatin in patients with progressive metastatic or unresectable colorectal cancer or other solid tumors.

SECONDARY OBJECTIVES:

I. Determine the toxicity of this regimen in these patients. II. Determine the pharmacokinetics of oxaliplatin, fluorouracil, and suberoylanilide hydroxamic acid in these patients.

OUTLINE: This is a dose-escalation study of suberoylanilide hydroxamic acid (SAHA).

Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.

After completion of study treatment, patients are followed for 4 weeks. ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Colorectal Neoplasms
Rectal Neoplasms
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage III Colon Cancer
Stage III Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Clinical Trial Details

NCT number	NCT00138177
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 1
Start date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01828775` - Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment	N/A
Terminated	`NCT01642342` - Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors	Phase 1
Completed	`NCT00002950` - Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT01705548` - Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis	N/A
Completed	`NCT02146222` - VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors	Phase 1
Terminated	`NCT01602627` - Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies	Phase 1
Completed	`NCT01191216` - 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors	Phase 1
Recruiting	`NCT00992303` - Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Recruiting	`NCT01137825` - Registry of Older Patients With Cancer
Suspended	`NCT00935090` - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer	N/A
Completed	`NCT00924651` - Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy	Phase 3
Completed	`NCT00949949` - Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy	Phase 1
Withdrawn	`NCT00937417` - S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT00710632` - Screening to Predict Weight Loss in Patients With Cancer	N/A
Completed	`NCT00544596` - R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer	Phase 1
Completed	`NCT00573690` - Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT00436735` - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors	Phase 1
Completed	`NCT00352443` - S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00126620` - Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors	Phase 1
Completed	`NCT00121277` - Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors	Phase 1